The Antibiotic Resistance Laboratory Network
|
|
- Annabella Brooks
- 6 years ago
- Views:
Transcription
1 The Antibiotic Resistance Laboratory Network 1
2 Antibiotic Resistance in the United States Sickens >2 million people per year Kills at least 23,000 people each year Plus 15,000 each year from C. difficile >$20B/year in healthcare costs Threatens modern medicine If we lose antibiotics, we lose the ability to treat patients with sepsis, cancer, provide organ transplants, and save victims of burns and trauma Need to act now or even drugs of last resort will soon be ineffective
3 Examples of Emerging AR Threats Pan-Resistant Gram-Negative Bacilli Enterobacteriaceae Acinetobacter spp. Pseudomonas aeruginosa Untreatable Neisseria gonorroheae Multi-Drug Resistant Candida spp. C. glabrata C. auris
4 Preventing AR Infections Works
5 Prevention Works
6 Prevention Guidelines
7
8 Coordinated Prevention Works Best State HAI/AR Prevention Programs Core capacity in all 50 states to detect, respond to, protect against HAI/AR threats Across all healthcare settings, networks of facilities in 25 states and 3 large cities working with health departments to: Better detect and respond to AR threats Prevent infections across healthcare
9 Detection Before Prevention
10 Lab Capacity Supported by the AR Solutions Initiative: Regional Labs Healthcare Labs State/Local Labs Regional Labs CDC
11 ARLN Data for Action Carbapenem-R Enterobacteriaceae (CRE) Interrupting CRE transmission in healthcare settings More accurate assess the burden of CRE Detect new or new trends in CRE types Carbapenem-R Pseudomonas aeruginosa and Acinetobacter spp. Detect plasmid-mediated carbapenemases ESBL-producing Enterobacteriaceae Detect mcr-1-mediated colistin resistance
12 ARLN Data for Action Salmonella spp. Measure the impact of antibiotic use in food-producing on human infections Neisseria gonorrhoeae Develop more accurate treatment guidelines Enhanced detect and response for new resistance in N. gonorrhoeae to identify and respond to outbreaks
13 ARLN Data for Action Candida spp. Detect resistance in strains that are not commonly Identification of C. auris and outbreak response Streptococcus pneumoniae Identify vaccine-escape strains Mycobacterium tuberculosis WGS to detect resistance and characterize transmission dynamics
14 Leveraging ARLN When New Threats Occur
15 More Resistant Bacteria and Bacteria that are Resistant to More Drugs An Example: 70 yo female hospitalized for an infection in her hip The patient recently traveled to India and was hospitalized for treatment of a hip fracture Infecting isolate: NDM-producing Klebsiella pneumoniae that was pan-resistant The patient developed septic shock and died
16 Leveraging technology and ARLN to identify therapeutic options for resistant infections.
17 Improved Communication of New AR Sends isolates with unusual resistance to ARLN Confirms & characterizes resistance. Initiates local prevention efforts CDC issues a national alert & sends alert to WHO WHO sends a global alert
18 In Conclusion
19 ARLN in Action Strategy and coordination for increased and sustained capacity Enhanced epi/lab collaboration at all levels Clinical lab partners for isolate sharing Improved communication among partners Improved coordination at CDC Rapid response for AR prevention EARLY SUCCESSES 556 suspected CRE Isolates: 194 Confirmed, 2 mcr-1 cases 5 CRE Colonization point prevalence surveys National infrastructure for detecting C. auris 1500 gonorrhea isolates: 300 sequenced, resistance trend tracking Nationally representative feasibility study of CIDT reflex culture Novel C. difficile data to interrupt transmission Enhancing national capacity for S. pneumoniae testing 19
20 National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) National Action Plan for CARB called for a CDC response to: Detect and -respond to resistant pathogens Prevent spread of resistant infections Encourage innovation for new strategies FY16: $160M appropriation will address AR with an ambitious, transformative approach, implementing CARB activities by 2020 For more information on CDC s key investments to combat antibiotic resistant bacteria, see:
21 Thank You Jean Patel
National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats
National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats Jean B. Patel, PhD, D(ABMM) Science Lead, Antibiotic Resistance and Coordination Unit Centers for
More informationThe Public Health Benefit of CRE Colonization Testing
The Public Health Benefit of CRE Colonization Testing Allison C Brown, PhD MPH Team Lead, AR Capacities and Special Studies Division of Healthcare Quality Promotion CDC Carbapenem Resistance Serious threat
More informationHOWARD A. ZUCKER, M.D., J.D. Commissioner
Date: April 5, 2018 To: Clinical Laboratories, Commercial Laboratories and Local Health Departments From: Wadsworth Center and NYSDOH Bureau of Healthcare-Associated Infections (BHAI) Laboratory Advisory
More information10/4/16. mcr-1. Emerging Resistance Updates. Objectives. National Center for Emerging and Zoonotic Infectious Diseases. Alex Kallen, MD, MPH, FACP
National Center for Emerging and Zoonotic Infectious Diseases Emerging Resistance Updates Alex Kallen, MD, MPH, FACP Lead Antimicrobial Resistance and Emerging Pathogens Team Prevention and Response Branch
More informationElectronic Test Orders and Results (ETOR)
Electronic Test Orders and Results (ETOR) Portal for Antibiotic Resistance (AR) Lab Network Problem Statement Antibiotic-resistant (AR) bacteria germs that don t respond to the drugs developed to kill
More informationNoelisa Montero, MPH. Epidemiologist Consultant. October 19, 2017 Connecticut Department of Public Health Healthcare Associated Infections Program
Carbapenem-resistant Enterobacteriaceae (CRE) in Connecticut: Collaborative Development of a Characterization Panel and Testing of Carbapenemase Genetic Markers, 2017 Noelisa Montero, MPH Epidemiologist
More informationThe role of an AMR reference laboratory
The role of an AMR reference laboratory Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright Primary purpose: regional AMR threats
More informationEmerging Infections, Outbreaks, and Steps of an Outbreak Investigation Across the Healthcare Continuum
Emerging Infections, Outbreaks, and Steps of an Outbreak Investigation Across the Healthcare Continuum Jennifer MacFarquhar, MPH, BSN, RN, CIC Heather Dubendris, MSPH North Carolina Division of Public
More informationMHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions
MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions Dr. Andrew Walkty Medical Microbiologist, Diagnostic Services Manitoba (DSM) June. 17,
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationAntimicrobial resistance Fact sheet N 194 Updated April 2014
Antimicrobial resistance Fact sheet N 194 Updated April 2014 Key facts Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by
More informationEmerging Infections, Outbreaks, and Steps of an Outbreak Investigation Across the Healthcare Continuum
Emerging Infections, Outbreaks, and Steps of an Outbreak Investigation Across the Healthcare Continuum Jennifer MacFarquhar, MPH, BSN, RN, CIC Heather Dubendris, MSPH North Carolina Division of Public
More informationTestimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and
Testimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and The Society for Healthcare Epidemiology of America (SHEA) to the U.S. House of Representatives Appropriations
More informationIsolation Precautions in Clinics
Purpose Audience General principles Possible Exposures To define isolation precautions in a clinic setting. Clinics Isolation status should be determined primarily by the suspected disease and/or pathogen.
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide
Transmitted by Jonathan Nurse, Director of Government Relations, IDSA The Infectious Diseases Society of America s (IDSA) Fiscal Year 2015 Funding Statement Submitted to the House Appropriations Subcommittee
More informationRegional Emergence of VIM producing carbapenem resistant Pseudomonas aeruginosa (VIM CRPA)
National Center for Emerging and Zoonotic Infectious Diseases Regional Emergence of VIM producing carbapenem resistant Pseudomonas aeruginosa (VIM CRPA) Chris Prestel, MD Epidemic Intelligence Service
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Carbapenemase-producing Enterobacteriaceae (CPE) infection or
More informationPublic Health Overview and Update
Public Health Overview and Update Jennifer A. Shuford, MD, MPH Texas Department of State Health Services Public Health Update Zoonoses Foodborne illnesses Influenza MDROs Images courtesy of CDC and APHIS
More informationCarbapenem-resistant Enterobacteriaceae (CRE): Coming to a hospital near you?
Carbapenem-resistant Enterobacteriaceae (CRE): Coming to a hospital near you? Jon Otter, PhD FRCPath Imperial College Healthcare NHS Trust www.reflectionsipc.com @jonotter Contents What s the problem?
More informationVaccine Innovation and Adult Immunization Landscape
Vaccine Innovation and Adult Immunization Landscape National Adult and Influenza Immunization Summit, May 12-14, 2015 Phyllis Arthur Senior Director Vaccines, Immunotherapeutics & Diagnostics Policy parthur@bio.org
More informationNew Mexico Emerging Infections Program Overview. Joan Baumbach NM Department of Health September 23, 2016
New Mexico Emerging Infections Program Overview Joan Baumbach NM Department of Health September 23, 2016 Emerging Infections Program History Established in 1995 as population-based, scientific, public
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationShaun Yang, PhD, D(ABMM), MLS(ASCP) CM MB CM Assistant Professor of Pathology UNM Health Sciences Center Associate Director of Infectious Disease
Shaun Yang, PhD, D(ABMM), MLS(ASCP) CM MB CM Assistant Professor of Pathology UNM Health Sciences Center Associate Director of Infectious Disease Director of Molecular Infectious Disease TriCore Reference
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationONE IS A PROBLEM, TWO IS AN OUTBREAK: DETECTING AND RESPONDING TO OUTBREAKS IN LONG-TERM CARE FACILITIES. May 17, 2018
ONE IS A PROBLEM, TWO IS AN OUTBREAK: DETECTING AND RESPONDING TO OUTBREAKS IN LONG-TERM CARE FACILITIES May 17, 2018 Jennifer MacFarquhar, MPH, BSN, RN, CIC Moderator: Wanda Lamm, RN, BSN, CIC, FAPIC
More informationAntimicrobial Resistance Surveillance Data Requirements for Priority Organisms
Antimicrobial Resistance Surveillance Data Requirements for Priority Organisms The Communicable and Infectious Disease Steering Committee Antimicrobial Resistance Surveillance Task Group Final Report to
More informationBSI. Candida auris: A globally emerging multidrug-resistant yeast 5/19/2017. First report of C. auris from Japan in 2009
5/9/7 BSI Candida auris: A globally emerging multidrug-resistant yeast Mycotic Diseases Branch DFWED Friday Seminar August 6, 6 National Center for Emerging and Zoonotic Infectious Diseases Division of
More information31/08/2017. Point Prevalence Survey for Antimicrobial Resistant Organisms in Canadian Long- Term Facilities. Overview
Point Prevalence Survey for Antimicrobial Resistant Organisms in Canadian Long- Term Facilities IPAC Canada 2017 National Education Conference June 20, 2017 Denise Gravel and the PHAC-IPAC Canada LTC Working
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationCarbapenemase Producing Enterobacteriaceae (CPE)
Carbapenemase Producing Enterobacteriaceae (CPE) Understanding The Public Health Emergency Professor Martin Cormican HSE National Lead for Health Care Associated Infection and Antimicrobial Resistance
More informationNational Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention Invasive Candidiasis
More information9/18/2018. Invasive Candidiasis. AR Lab Network Candida Testing. Most Common Healthcare Associated Bloodstream Infection in the United States?
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Invasive Candidiasis Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention
More informationCouncil for Outbreak Response: Healthcare-Associated Infections & Antibiotic-Resistant Pathogens (CORHA) HICPAC December 1, 2016
Council for Outbreak Response: Healthcare-Associated Infections & Antibiotic-Resistant Pathogens (CORHA) HICPAC December 1, 2016 National Center for Emerging and Zoonotic Infectious Diseases Division of
More informationHOSPITAL INFECTION CONTROL
HOSPITAL INFECTION CONTROL Objectives To be able to define hospital acquired infections discuss the sources and routes of transmission of infections in a hospital describe methods of prevention and control
More informationUpdates: Candida Epidemiology and Candida auris
National Center for Emerging and Zoonotic Infectious Diseases Updates: Candida Epidemiology and Candida auris Tom Chiller MD MPHTM Chief, Mycotic Diseases Branch My usual Disclosure! 1 Candidemia surveillance
More informationConference For Healthcare Transparency & Patient Safety. Kraig Humbaugh, MD, MPH Lexington, KY November 13, 2015
Conference For Healthcare Transparency & Patient Safety Kraig Humbaugh, MD, MPH Lexington, KY November 13, 2015 2 Objectives After this presentation, participants will be able to: Explain the importance
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Carbapenem-resistant Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 47: Carbapenem-resistant Enterobacteriaceae Authors E-B Kruse, MD H. Wisplinghoff, MD Chapter Editor Michelle Doll, MD, MPH) Topic Outline Key Issue Known
More informationNONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN
NONFERMENTING GRAM NEGATIVE RODS April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic limitations to assessing carbapenem resistance in nonfermenting GNRs Discuss antimicrobial
More informationHaemophilus influenzae and its invisibility cloak. Anna Strain Virology Supervisor/VPD Reference Center Coordinator June 5, 2018
Haemophilus influenzae and its invisibility cloak Anna Strain Virology Supervisor/VPD Reference Center Coordinator June 5, 2018 Haemophilus influenzae Gram negative aerobic coccobacilli Pfeiffer s Bacillus-
More informationDetecting CRE. what does one need to do?
5 th ICAN Conference, Harare 4 th November 2014 Room 2: 10:30-12:00 Detecting CRE (Carbapenem-resistant Enterobacteriaceae) what does one need to do? Dr Nizam Damani Associate Medical Director Infection
More informationBurns outbreaks - the UHB experience
Burns outbreaks - the UHB experience Dr Mark Garvey Mr Craig Bradley Principal Clinical Scientist in Microbiology Lead Nurse Infection Prevention Director of the Hospital Infection Research Laboratory
More informationQUESTION 1: THE BACTERIUM MOST LIKELY TO BE TRANSMITTED FROM MOTHER TO INFANT DURING LABOR AND CAUSE NEONATAL SEPSIS IS: A. Escherichia coli B.
PRACTICE QUESTIONS QUESTION 1: THE BACTERIUM MOST LIKELY TO BE TRANSMITTED FROM MOTHER TO INFANT DURING LABOR AND CAUSE NEONATAL SEPSIS IS: A. Escherichia coli B. Staphylococcus aureus C. Group B Streptococcus
More informationProposals for E.coli surveillance Informatics- proposal for the Infection. VRE molecular epidemiology AMR alerts HPA repatriation Rotavirus
HPS Update Proposals for E.coli surveillance Informatics- proposal for the Infection Intelligence Platform (IIP) VRE molecular epidemiology AMR alerts HPA repatriation Rotavirus IIP Strategic intent.to
More informationRecommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals
Recommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals Minnesota Department of Health 11/2011 Infectious Disease Epidemiology,
More informationThe Year in Infection Control
The Year in Infection Control Andie Lee Departments of Infectious Diseases and Microbiology Royal Prince Alfred Hospital Sydney, Australia 1 1.223 million Pubmed publications last 12 months 2 Selection
More informationLourdes Hospital Infection Prevention and Control
Lourdes Hospital Infection Prevention and Control Lourdes Infection Prevention Program Ultimate goal: To protect the patient To protect the healthcare workers, visitors and others in the environment To
More informationEnterobacteriaceae? ECDC EVIDENCE BRIEF. Why focus on. Update on the spread of carbapenemase-producing Enterobacteriaceae in Europe
ECDC EVIDENCE BRIEF November 2015 Update on the spread of carbapenemase-producing Enterobacteriaceae in Europe Summary of the May 2015 expert assessment The EuSCAPE project This ECDC Evidence Brief identifies
More informationInfection Control Strategies to Avoid Carbapenam Resistance in Hospitals. Victor Lim International Medical University Malaysia
Infection Control Strategies to Avoid Carbapenam Resistance in Hospitals Victor Lim International Medical University Malaysia Outline of Lecture 1. Carbapenam resistance 2. Epidemiology of carbapenam resistance
More informationPreventing & Controlling the Spread of Infection
Preventing & Controlling the Spread of Infection Contributors: Alice Pong M.D., Hospital Epidemiologist Chris Abe, R.N., Senior Director Ancillary and Support Services Objectives Review the magnitude of
More informationEmerging Pathogens and Outbreaks
Emerging Pathogens and Outbreaks Derek Forster, MD Assistant Professor of Medicine, Division of Infectious Diseases Medical Director, Infection Prevention and Control UK HealthCare Objectives Review emerging
More informationBurns outbreaks - the UHB experience
Burns outbreaks - the UHB experience Dr Mark Garvey Principal Clinical Scientist in Microbiology Director of the Hospital Infection Research Laboratory Associate Director of Infection Prevention and Control
More informationDetermining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing
AAC Accepted Manuscript Posted Online 8 August 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.00838-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 1 2 Determining the
More informationHOSPITAL EPIDEMOLOGY AND INFECTION CONTROL: STANDARD AND TRANSMISSION-BASED ISOLATION
Appendix 1: Carbapenem-Resistant Enterobacteriacaea (CRE) I. Definition: 2015 CDC definition of CRE are Enterobacteriaceae 1 that are: A. Resistant to any carbapenem antimicrobial (i.e., minimum inhibitory
More informationAPHL Next Generation Sequencing (NGS) Survey
Next Generation Sequencing 1. How long has your lab had a sequencer? [If lab does not have a sequencer go to 1a1 through 1a3 and then end survey] [If lab does have a sequencer continue to 1a and the rest
More informationCURRENT INFECTIOUS DISEASE ISSUES. 11/2/15 Regina Won, MD
CURRENT INFECTIOUS DISEASE ISSUES 11/2/15 Regina Won, MD Disclosures None Objectives Discuss common organisms seen on the wards Discuss infection control issues associated with these common organisms Discuss
More informationREQUEST FOR PROPOSAL Product opportunity assessment for the development of vaccines against pathogens with high levels of antimicrobial resistance
REQUEST FOR PROPOSAL Product opportunity assessment for the development of vaccines against pathogens with high levels of antimicrobial resistance INTRODUCTION The Wellcome Trust is the world s second
More informationGlobal Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE)
Global Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE) Mitchell J. Schwaber, MD MSc Director, National Center for Infection Control Ministry of Health State of Israel November 27, 2012 1
More informationCouncil for Outbreak Response: Healthcare-Associated Infections Antibiotic-Resistant Pathogens
Council for Outbreak Response: Healthcare-Associated Infections Antibiotic-Resistant Pathogens Joe Perz, DrPH MA CDC/DHQP CORHA Governance Committee Member Spring SHEA Meeting April 18, 2018 Updated May
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationIP Lab Webinar 8/23/2012
2 What Infection Preventionists need to know about the Laboratory Anne Maher, MS, M(ASCP), CIC Richard VanEnk PhD, CIC 1 Objectives Describe what the laboratory can do for you; common laboratory tests
More informationIn-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 01 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.701.342
More informationAdvanced Molecular Detection and Epidemiology
National Center for Emerging and Zoonotic Infectious Diseases Advanced Molecular Detection and Epidemiology LCDR Alison Laufer Halpin, PhD Lead, Metagenomics and Molecular Biology Team Clinical and Environmental
More informationCarbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School
Carbapenemases in Enterobacteriaceae: 2012 Prof P. Nordmann Bicêtre hospital, South-Paris Med School March 21, 2012 Trends in Molecular Medecine NDM IMP OXA-48 KPC VIM ALERT VI M KPC KPC NDM I MP OXA-
More informationEmerging Infectious Diseases Australia is not an Island
Emerging Infectious Diseases Australia is not an Island Bart Currie Global and Tropical Health Division Menzies School of Health Research, Darwin Infectious Diseases Department, Royal Darwin Hospital Borneo
More informationThe Carbapenemase Producing Enterobacteriaceae (CPE) Epidemic Why it matters? What it is? What Can You Do About It?
The Carbapenemase Producing Enterobacteriaceae (CPE) Epidemic Why it matters? What it is? What Can You Do About It? Martin Cormican National Lead for Health Care Associated Infection and Antimicrobial
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More information5 HEALTH PRIORITIES, 10 OUTCOME MEASURES
Community Health Needs Assessment 2017-2019 5 HEALTH PRIORITIES, 10 OUTCOME MEASURES improving the health of our community in all we do 1 SEPSIS Click on each to learn more Roughly 50% of patients who
More informationUsing Big Data to Prevent Infections
Using Big Data to Prevent Infections A thought paper by Scalable Health Big Data Analytics Reduces Infections in Hospitals Healthcare Associated Infections (HAIs) are developed while patients are receiving
More informationMechanisms of Pathogenicity
Mechanisms of Pathogenicity The Microbes Fight Back Medically important bacteria Salmonella Bacillus anthracis Shigella dysenteriae Campylobacter Shigella sonnei Clostridium botulinum Staphylococcus aureus
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationMDROs and other exciting things What You Need to Know in Long-Term Care
MDROs and other exciting things What You Need to Know in Long-Term Care 1 April 12, 2018 Toni Foos, RN, BSN, CIC Infection Prevention Manager Colorado Hospital Association Today s Call is Provided by Telligen
More informationMartin Friede Vaccine workstream Liz Tayler AMR secretariat Global action plan on antimicrobial resistance
WHO Global Action Plan on Antimicrobial Resistance Martin Friede Vaccine workstream Liz Tayler AMR secretariat AMR a global health threat Resistant bacterial infections cause about 50 000 deaths in the
More informationThink Globally: Strategies to Improve the Culture of Antibiotic Prescribing
Think Globally: Strategies to Improve the Culture of Antibiotic Prescribing October 11, 2017 Paul Lewis, PharmD, BCPS (AQ-ID) Johnson City Medical Center Johnson City, TN 1 Outline Introduction to stewardship
More informationEmergence of non-kpc carbapenemases: NDM and more
Emergence of non-kpc carbapenemases: NDM and more --- David Livermore Health Protection Agency, UK The first acquired carbapenemase to be recognised in gram-negative bacteria was IMP-1, a metallo-type,
More informationDevelopment of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE)
Development of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE) Dr. Juliane Bernholz, Novartis (Coordinator) Dr. Andrea Appenzeller,
More informationNavigating Through Current and Emerging Issues in Outbreaks
Navigating Through Current and Emerging Issues in Outbreaks 7th GCC Conference on Infection Prevention and Control December 1-3, 2013 Kuwait City, Kuwait William R. Jarvis, M.D. Jason and Jarvis Associates,
More informationASLM Anti-microbial Resistance in Africa and Global Health Security. 9TH INTEREST WORKSHOP May 2015 Harare
ASLM Anti-microbial Resistance in Africa and Global Health Security 9TH INTEREST WORKSHOP 2015 8 May 2015 Harare Recent Jim O Neil Report commissioned by the UK government predicts dire consequences of
More informationTP Larry Tsai, MD Chief Medical Officer Tetraphase Pharmaceuticals
TP-676 Larry Tsai, MD Chief Medical Officer Tetraphase Pharmaceuticals Tetraphase Pharmaceuticals Overview Tetraphase is developing novel antibiotics for serious and life-threatening Gram-negative MDR
More informationCenters for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary
Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary The President s FY 2009 Budget Request for the Centers for Disease Control and Prevention (CDC) discretionary funding is
More informationSpread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory
Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory Olga Perovic*, Ashika Singh-Moodley, Samantha Iyaloo 5 th November
More informationby author Epidemiology of infections in the ICU
Epidemiology of infections in the ICU Anastasia Antoniadou Internal Medicine Infectious Diseases Assistant Professor Athens University Medical School University General Hospital ATTIKON Epidemiology of
More informationWHAT S NEW WITH OSHA AND INFECTION CONTROL?
WHAT S NEW WITH OSHA AND INFECTION CONTROL? Injury reports Affects employers with >15 employees If worker loses a limb or an eye, or is hospitalized, must report directly to OSHA/MIOSHA Mary Govoni, CDA,
More informationVIII Updating Course of Antimicrobials and Infectious Diseases 2018
The Author 2018. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
More informationINFECTIOUS DISEASE. Page 2
Infectious disease Advantages OF TESTING INFECTIOUS DISEASE We are in the middle of a paradigm shift in infectious disease diagnostic testing. As we move from targeted infectious disease testing to a syndromic
More informationEuropean Society of Clinical Microbiology and Infectious Diseases (ESCMID) Health in Europe: A Strategic Approach
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Health in Europe: A Strategic Approach Comments by the ESCMID Executive Committee, http://www.escmid.org The European Society
More informationEarly identification and management of CPE risk in the Emergency Department.
Early identification and management of CPE risk in the Emergency Department. Jo-Anne McShane 1, Andrew Maclean 1,2, Leanne Houston 4, Helen Marquand 4, Madeleine Smith 1,Mary O Reilly 1,2,3 Acknowledgements:
More informationTHE EVOLVING LANDSCAPE OF INFECTION PREVENTION: RISK MITIGATION THROUGH INFECTION SURVEILLANCE
THE EVOLVING LANDSCAPE OF INFECTION PREVENTION: RISK MITIGATION THROUGH INFECTION SURVEILLANCE Yves Crehore Software Product Manager, R.N. RL Solutions AGENDA Current Infectious Landscape Partnership:
More informationEpidemiology of Infectious Complications of H1N1 Influenza Virus Infection
Epidemiology of Infectious Complications of H1N1 Influenza Virus Infection Lyn Finelli, DrPH, MS Lead, Influenza Surveillance and Outbreak Response Epidemiology and Prevention Branch Influenza Division
More informationPresented at the annual meeting of the American Society of Microbiology, June 1-5, 2017, New Orleans, LA, USA
Is Associated With Improved Survival and Safety Compared to Colistin in Serious Carbapenemresistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study Lynn E. Connolly 1, Adrian M. Jubb 1,
More information9/7/2017. If You Did This Today You Probably Got Poo On Your Hands Do You Know How to Get it Off! The Tongue Twister & The Pantomine TITLE
TITLE Martin Cormican National Lead for Health Care Associated Infection and Antimicrobial Resistance hcainational.lead@hse.ie If You Did This Today You Probably Got Poo On Your Hands Do You Know How to
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in
Testimony of the Infectious Diseases Society of America (IDSA) on the Fiscal Year 2018 Department of Health and Human Services Budget Prepared for the U.S. House of Representatives Subcommittee on Labor-HHS-Education
More informationerils of Manufactured Diseases ented by Christopher Bossert
erils of Manufactured Diseases ented by Christopher Bossert Introduction: Superbugs In 1928, penicillin was discovered the first true antibiotic. From then until now, we have steadily developed stronger
More informationInfectious Diseases-HAI, Infectious Diseases Arizona Department of Health Services, Public Health Services. Phoenix, Arizona. Assignment Description
Infectious Diseases-HAI, Infectious Diseases Arizona Department of Health Services, Public Health Services Phoenix, Arizona Assignment Description The Fellow will be situated in the the Office of Infectious
More informationBefore an outbreak - what to do after first MDR Gram-negatives enter your hospital?
Before an outbreak - what to do after first MDR Gram-negatives enter your hospital? Jon Otter, PhD FRCPath Imperial College London j.otter@imperial.ac.uk @jonotter Blog: www.reflectionsipc.com Slides:
More informationStandard Operating Procedures for Projects/ Tasks using EpiData Center HL7 Data
Standard Operating Procedures for Projects/ Tasks using EpiData Center HL7 Data NMCPHC-EDC-TR-118-2016 Last updated 10 March 2016 1 Background EpiData Center utilizes the Health Level 7 (HL7) formatted
More informationDetecting Carbapenemase-Producing Enterobacteriaceae: why isn t there a single best method?
Detecting Carbapenemase-Producing Enterobacteriaceae: why isn t there a single best method? Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown
More informationCAVIWIPES1. Technical Bulletin
CAVIWIPES1 Technical Bulletin CaviWipes1 Disinfecting Towelettes are non-woven disposable towelettes pre-saturated with CaviCide1. CaviWipes 1 are intended for use in health care settings such as hospitals,
More informationIS THE UK WELL PREPARED FOR A REPEAT OF THE 1918 INFLUENZA PANDEMIC?
Cambridge Judge Business School Centre for Risk Studies IS THE UK WELL PREPARED FOR A REPEAT OF THE 1918 INFLUENZA PANDEMIC? Dr Andrew Coburn Chief Scientist Cambridge Centre for Risk Studies 5 December
More informationSepsis Treatment: Early Identification Remains the Key Issue
Sepsis Treatment: Early Identification Remains the Key Issue Marin H. Kollef, MD Professor of Medicine Washington University School of Medicine Director, Medical Critical Care Director, Respiratory Care
More informationProposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC),
This document is scheduled to be published in the Federal Register on 11/16/2017 and available online at https://federalregister.gov/d/2017-24804, and on FDsys.gov BILLING CODE: 4163-18-P DEPARTMENT OF
More information